Cargando…

Synthetic high-density lipoprotein nanodisks for targeted withalongolide delivery to adrenocortical carcinoma

Adrenocortical carcinoma (ACC) is a rare endocrine malignancy and has a 5-year survival rate of <35%. ACC cells require cholesterol for steroid hormone production, and this requirement is met via expression on the cell surface of a high level of SRB1, responsible for the uptake of high-density li...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuai, Rui, Subramanian, Chitra, White, Peter T, Timmermann, Barbara N, Moon, James J, Cohen, Mark S, Schwendeman, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593402/
https://www.ncbi.nlm.nih.gov/pubmed/28919755
http://dx.doi.org/10.2147/IJN.S140591
_version_ 1783263027339984896
author Kuai, Rui
Subramanian, Chitra
White, Peter T
Timmermann, Barbara N
Moon, James J
Cohen, Mark S
Schwendeman, Anna
author_facet Kuai, Rui
Subramanian, Chitra
White, Peter T
Timmermann, Barbara N
Moon, James J
Cohen, Mark S
Schwendeman, Anna
author_sort Kuai, Rui
collection PubMed
description Adrenocortical carcinoma (ACC) is a rare endocrine malignancy and has a 5-year survival rate of <35%. ACC cells require cholesterol for steroid hormone production, and this requirement is met via expression on the cell surface of a high level of SRB1, responsible for the uptake of high-density lipoproteins (HDLs), which carry and transport cholesterol in vivo. Here, we describe how this natural lipid carrier function of SRB1 can be utilized to improve the tumor-targeted delivery of a novel natural product derivative – withalongolide A 4,19,27-triacetate (WGA-TA) – which has shown potent antitumor efficacy, but poor aqueous solubility. Our strategy was to use synthetic HDL (sHDL) nanodisks, which are effective in tumor-targeted delivery due to their smallness, long circulation half-life, documented safety, and ability to bind to SRB1. In this study, we prepared sHDL nanodisks using an optimized phospholipid composition combined with ApoA(1) mimetic peptide (22A), which has previously been tested in clinical trials, to load WGA-TA. Following optimization, WGA-TA nanodisks showed drug encapsulation efficiency of 78%, a narrow particle size distribution (9.81±0.41 nm), discoid shape, and sustained drug release in phosphate buffered saline. WGA-TA-sHDL nanodisks exhibited higher cytotoxicity in the ACC cell line H295R half maximal inhibitory concentration ([IC(50)] 0.26±0.045 μM) than free WGA-TA (IC(50) 0.492±0.115 μM, P<0.05). Fluorescent dye-loaded sHDL nanodisks efficiently accumulated in H295R adrenal carcinoma xenografts 24 hours following dosing. Moreover, daily intraperitoneal administration of 7 mg/kg WGA-TA-loaded sHDL nanodisks significantly inhibited tumor growth during 21-day administration to H295R xenograft-bearing mice compared to placebo (P<0.01). Collectively, these results suggest that WGA-TA-loaded nanodisks may represent a novel and beneficial therapeutic strategy for the treatment of ACC.
format Online
Article
Text
id pubmed-5593402
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-55934022017-09-15 Synthetic high-density lipoprotein nanodisks for targeted withalongolide delivery to adrenocortical carcinoma Kuai, Rui Subramanian, Chitra White, Peter T Timmermann, Barbara N Moon, James J Cohen, Mark S Schwendeman, Anna Int J Nanomedicine Original Research Adrenocortical carcinoma (ACC) is a rare endocrine malignancy and has a 5-year survival rate of <35%. ACC cells require cholesterol for steroid hormone production, and this requirement is met via expression on the cell surface of a high level of SRB1, responsible for the uptake of high-density lipoproteins (HDLs), which carry and transport cholesterol in vivo. Here, we describe how this natural lipid carrier function of SRB1 can be utilized to improve the tumor-targeted delivery of a novel natural product derivative – withalongolide A 4,19,27-triacetate (WGA-TA) – which has shown potent antitumor efficacy, but poor aqueous solubility. Our strategy was to use synthetic HDL (sHDL) nanodisks, which are effective in tumor-targeted delivery due to their smallness, long circulation half-life, documented safety, and ability to bind to SRB1. In this study, we prepared sHDL nanodisks using an optimized phospholipid composition combined with ApoA(1) mimetic peptide (22A), which has previously been tested in clinical trials, to load WGA-TA. Following optimization, WGA-TA nanodisks showed drug encapsulation efficiency of 78%, a narrow particle size distribution (9.81±0.41 nm), discoid shape, and sustained drug release in phosphate buffered saline. WGA-TA-sHDL nanodisks exhibited higher cytotoxicity in the ACC cell line H295R half maximal inhibitory concentration ([IC(50)] 0.26±0.045 μM) than free WGA-TA (IC(50) 0.492±0.115 μM, P<0.05). Fluorescent dye-loaded sHDL nanodisks efficiently accumulated in H295R adrenal carcinoma xenografts 24 hours following dosing. Moreover, daily intraperitoneal administration of 7 mg/kg WGA-TA-loaded sHDL nanodisks significantly inhibited tumor growth during 21-day administration to H295R xenograft-bearing mice compared to placebo (P<0.01). Collectively, these results suggest that WGA-TA-loaded nanodisks may represent a novel and beneficial therapeutic strategy for the treatment of ACC. Dove Medical Press 2017-09-06 /pmc/articles/PMC5593402/ /pubmed/28919755 http://dx.doi.org/10.2147/IJN.S140591 Text en © 2017 Kuai et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Kuai, Rui
Subramanian, Chitra
White, Peter T
Timmermann, Barbara N
Moon, James J
Cohen, Mark S
Schwendeman, Anna
Synthetic high-density lipoprotein nanodisks for targeted withalongolide delivery to adrenocortical carcinoma
title Synthetic high-density lipoprotein nanodisks for targeted withalongolide delivery to adrenocortical carcinoma
title_full Synthetic high-density lipoprotein nanodisks for targeted withalongolide delivery to adrenocortical carcinoma
title_fullStr Synthetic high-density lipoprotein nanodisks for targeted withalongolide delivery to adrenocortical carcinoma
title_full_unstemmed Synthetic high-density lipoprotein nanodisks for targeted withalongolide delivery to adrenocortical carcinoma
title_short Synthetic high-density lipoprotein nanodisks for targeted withalongolide delivery to adrenocortical carcinoma
title_sort synthetic high-density lipoprotein nanodisks for targeted withalongolide delivery to adrenocortical carcinoma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593402/
https://www.ncbi.nlm.nih.gov/pubmed/28919755
http://dx.doi.org/10.2147/IJN.S140591
work_keys_str_mv AT kuairui synthetichighdensitylipoproteinnanodisksfortargetedwithalongolidedeliverytoadrenocorticalcarcinoma
AT subramanianchitra synthetichighdensitylipoproteinnanodisksfortargetedwithalongolidedeliverytoadrenocorticalcarcinoma
AT whitepetert synthetichighdensitylipoproteinnanodisksfortargetedwithalongolidedeliverytoadrenocorticalcarcinoma
AT timmermannbarbaran synthetichighdensitylipoproteinnanodisksfortargetedwithalongolidedeliverytoadrenocorticalcarcinoma
AT moonjamesj synthetichighdensitylipoproteinnanodisksfortargetedwithalongolidedeliverytoadrenocorticalcarcinoma
AT cohenmarks synthetichighdensitylipoproteinnanodisksfortargetedwithalongolidedeliverytoadrenocorticalcarcinoma
AT schwendemananna synthetichighdensitylipoproteinnanodisksfortargetedwithalongolidedeliverytoadrenocorticalcarcinoma